Quick Answer
Climb Bio, Inc. reported Operating Income Loss of -$67.88 million for the year ending 2025.
- Climb Bio, Inc. showed an increase of +17.2% in Operating Income Loss from 2024 to 2025.
- This data is from Climb Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: -$1.61 million | Q3 2020: -$2.26 million | Q1 2021: -$6.88 million | Q2 2021: -$8.71 million | Q3 2021: -$9.38 million | Q1 2022: -$13.13 million | Q2 2022: -$13.70 million | Q3 2022: -$8.75 million | Q1 2023: -$23.44 million | Q2 2023: -$6.71 million | Q3 2023: -$5.00 million | Q1 2024: -$3.01 million | Q2 2024: -$56.37 million | Q3 2024: -$11.73 million | Q1 2025: -$23.02 million | Q2 2025: -$10.68 million | Q3 2025: -$14.89 million.
- Over the full 6 years of available data (2020 to 2025), Climb Bio, Inc.'s Operating Income Loss has declined by 224.4%.
- Historical annual values: Fiscal year 2025: -$67.88 million | Fiscal year 2024: -$82.02 million | Fiscal year 2023: -$40.28 million | Fiscal year 2022: -$45.14 million | Fiscal year 2021: -$35.67 million | Fiscal year 2020: -$20.93 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: